CN-121992124-A - Application of microbial marker in preparation of hyperuricemia diagnosis product and hyperuricemia diagnosis device

Abstract

The invention provides application of a microbial marker in preparing a hyperuricemia diagnosis product and a hyperuricemia diagnosis device, and relates to the technical field of biomedicine. According to the invention, the intestinal flora composition of the crowd queue is analyzed by a high-throughput microorganism sequencing technology, and a group of core microorganism marker combinations capable of reliably predicting the occurrence tendency of hyperuricemia are identified and verified by using bioinformatics algorithms such as machine learning and the like. Finally, a device for diagnosing hyperuricemia is established based on the microbial markers, the device has high prediction accuracy, and a brand new, noninvasive and high clinical transformation potential tool is provided for early screening and risk stratification of hyperuricemia.

Inventors

• LUO YUAN
• ZHENG XIANGYI
• ZHANG HAITAO
• WANG GUANGYUN
• ZHU GUIZHEN
• Duan Fengsen
• CUI YUEYING
• YE QIAO
• MEI ZHUSONG

Assignees

• 中国人民解放军空军特色医学中心

Dates

Publication Date

20260508

Application Date

20260302

Claims (9)

1. 1. Use of an agent for detecting the abundance of a microorganism in feces, wherein the microorganism comprises firmicutes, bacteria, cag, 124, paraprefotella, clara, clostridium and bacterioides.
2. 2. The use according to claim 1, wherein the composition is administered to a healthy subject, in the feces of hyperuricemia patients, the abundance of firmicutes.
3. 3. The use according to claim 1, wherein the abundance of paraprefotella clara is down-regulated in the feces of hyperuricemia patients compared to healthy subjects.
4. 4. The use according to claim 1, wherein the abundance of clostridium in the faeces of hyperuricemia patients is down-regulated compared to healthy subjects.
5. 5. The use according to claim 1, wherein the composition is administered to a healthy subject, in the feces of hyperuricemia patients, the abundance of bacteriodes.
6. 6. The use according to claim 1, wherein the microbial abundance in the feces is detected by microbial sequencing and bioinformatic analysis.
7. 7. A device for diagnosing hyperuricemia, which is characterized by comprising a data acquisition module and a classification module; the data acquisition module is used for acquiring microorganism abundance data of the excrement of the to-be-detected subject; The classification module is used for inputting the microbial abundance data of the excrement of the to-be-detected subject into a pre-trained classification model, classifying the microbial abundance data of the excrement of the to-be-detected subject through the classification model, and predicting whether the to-be-detected subject suffers from hyperuricemia or evaluating whether the to-be-detected subject is a hyperuricemia susceptible population; The classification model is obtained through training by the following method: a. Obtaining microbial abundance data for feces from healthy subjects and hyperuricemia patients; b. Training a classification model by utilizing the microorganism abundance data to obtain a pre-trained classification model; The microorganisms include Firmics. Bacteria. CAG.124, paraprevatella. Clara, clostridia. Bacteria and Bactoides. Intestinalis.
8. 8. The device of claim 7, wherein the microbial abundance in the feces is detected by microbial sequencing and bioinformatic analysis.
9. 9. The apparatus of claim 7, wherein the classification model comprises a random forest model.

Description

Application of microbial marker in preparation of hyperuricemia diagnosis product and hyperuricemia diagnosis device Technical Field The invention relates to the technical field of biomedicine, in particular to an application of a microbial marker in preparing a hyperuricemia diagnosis product and a hyperuricemia diagnosis device. Background Hyperuricemia (HUA) constitutes a significant public health challenge as an independent risk factor for gout, chronic kidney disease, and cardiovascular and cerebrovascular diseases. The core bottleneck of current control strategies is the lack of effective early warning tools. Depending on the clinical criteria of single blood uric acid detection, it is only possible to perform "post-diagnosis" after the occurrence of a metabolic imbalance, failing to identify a large number of "sub-clinical" high risk individuals whose uric acid levels are at "normal high values" or severely fluctuating, but which already have a clear hyperuricemic tendency. Recent studies have revealed that intestinal microbiomes play a critical role in human purine and uric acid metabolism. Intestinal flora not only directly participates in ingestion of dietary purine and intestinal decomposition of uric acid (about 30% of total excretion of uric acid), but also indirectly regulates synthesis of uric acid and renal excretion by affecting systemic inflammatory states, insulin sensitivity and intestinal barrier function. Thus, disorders of the intestinal microbiome (dysbacteriosis) are considered as critical environmental and physiological mediators of the occurrence and progression of hyperuricemia. This provides a completely new and potentially powerful source of biomarkers for early risk assessment of hyperuricemia. However, most of the current studies remain describing differences in overall flora structure between hyperuricemic patients and healthy people, or finding cross-sectional correlations of minority bacteria with uric acid levels. These findings have not yet been translated into accurate predictive tools that can be used for clinical or health management. In view of this, the present invention has been made. Disclosure of Invention A first object of the present invention is to provide an application of a reagent for detecting the abundance of microorganisms in feces in preparing a product for diagnosing hyperuricemia, so as to solve the above technical problems. A second object of the present invention is to provide a device for diagnosing hyperuricemia. In order to achieve the above object, the following technical scheme is adopted: In a first aspect, the invention provides the use of an agent for detecting the abundance of microorganisms including Firmics, bacteria, CAG.124, parapreviella, clara, clostridia, bacteria and bacteria, intestinalis in the manufacture of a product for diagnosing hyperuricemia. Firmics. Bacteria. CAG.124, paraprevatella. Clara, clostridia. Bacteria and Bactroides. Intestinalis all refer to species of bacteria. As a further aspect, in comparison to a healthy subject, in the feces of hyperuricemia patients, the abundance of firmicutes. As a further aspect, the abundance of paraprefotella clara is down-regulated in the stool of a hyperuricemia patient compared to a healthy subject. As a further aspect, the abundance of clostridium in the feces of hyperuricemia patients is down-regulated compared to healthy subjects. As a further technical approach, the abundance of bacteriodes in the feces of hyperuricemia patients is down-regulated compared to healthy subjects. As a further technical scheme, the microbial abundance in the feces is detected by gene sequencing and bioinformatics analysis. In a second aspect, the present invention provides a device for diagnosing hyperuricemia, including a data acquisition module, a classification module; the data acquisition module is used for acquiring microorganism abundance data of the excrement of the to-be-detected subject; The classification module is used for inputting the microbial abundance data of the excrement of the to-be-detected subject into a pre-trained classification model, classifying the microbial abundance data of the excrement of the to-be-detected subject through the classification model, and predicting whether the to-be-detected subject suffers from hyperuricemia or evaluating whether the to-be-detected subject is a hyperuricemia susceptible population; The classification model is obtained through training by the following method: a. Obtaining microbial abundance data for feces from healthy subjects and hyperuricemia patients; b. Training a classification model by utilizing the microorganism abundance data to obtain a pre-trained classification model; The microorganisms include Firmics. Bacteria. CAG.124, paraprevatella. Clara, clostridia. Bacteria and Bactoides. Intestinalis. As a further technical scheme, the microbial abundance in the feces is detected by gene sequencing and bioinformatics analysis. As a